Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Pearl Kwong

Pediatric Dermatology Jacksonville, FL Medical Doctor

NPI 1043309909 CMS profile 620680

10175 Fortune Pkwy Unit 1203, Jacksonville, FL 32256

Open in the dashboard

General payments

$3,187,351

3,645 records reported · program years 2019–2025

Research payments

$55,202

Paid to them · 17 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$4,783,811 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Pearl Kwong of Jacksonville, FL is reported in the CMS Open Payments database as having received $3,187,351 across 3,645 general payments and $55,202 in research payments paid to them. Separately, studies naming them as principal investigator received $4,783,811 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Pediatric Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $748,093 639
2024 General $604,472 633
2024 Research $4,484 2
2023 General $610,203 649
2022 General $567,118 580
2022 Research $25,287 4
2021 General $229,695 365
2021 Research $4,617 4
2020 General $123,134 262
2020 Research $2,328 4
2019 General $304,636 517
2019 Research $18,487 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pearl Kwong
  • Pediatric Dermatology median
  • Middle half of Pediatric Dermatology
  • National median

In program year 2025, general payments to Pearl Kwong were reported at $748,093. Among 172 Pediatric Dermatology profiles paid that year, the median was $302 and the middle half received between $110 and $2,128.

Show as a table
Year Pearl Kwong Pediatric Dermatology median Middle half National median
2019 $304,636 $280 $89–$1,853 $163
2020 $123,134 $263 $71–$2,376 $114
2021 $229,695 $227 $69–$1,800 $132
2022 $567,118 $289 $69–$1,516 $149
2023 $610,203 $537 $114–$3,255 $160
2024 $604,472 $437 $114–$2,693 $164
2025 $748,093 $302 $110–$2,128 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $578,372 572 payments
  2. Genzyme Corporation $493,032 357 payments
  3. Pfizer Inc. $337,377 336 payments
  4. Incyte Corporation $288,147 236 payments
  5. Lilly USA, LLC $265,229 310 payments
  6. AbbVie, Inc. $261,157 275 payments
  7. Arcutis Biotherapeutics, Inc. $236,311 221 payments
  8. Sun Pharmaceutical Industries Inc. $123,523 146 payments
  9. Galderma Laboratories, L.P. $98,866 186 payments
  10. Organon LLC $86,013 67 payments
  11. Other $419,324 939 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,188,719 638 payments
  2. Travel and Lodging $363,632 878 payments
  3. Consulting Fee $351,596 110 payments
  4. Honoraria $135,500 43 payments
  5. Food and Beverage $100,961 1,955 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $40,379 12 payments
  7. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $6,100 3 payments
  8. Education $347 5 payments
  9. Gift $117 1 payment
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $717,089 491 payments
  2. DUPIXENT Inflammation And Immunology $476,491 500 payments
  3. OPZELURA $281,007 222 payments
  4. RINVOQ $254,833 243 payments
  5. Zoryve $166,369 167 payments
  6. EUCRISA $146,922 193 payments
  7. CIBINQO $127,471 116 payments
  8. Winlevi $102,522 104 payments
  9. DUPIXENT Immunology And Inflammation $102,069 74 payments
  10. VTAMA $94,868 138 payments
  11. Other $791,871 1,580 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $27,490 13 payments
  2. Almirall LLC $18,487 2 payments
  3. Novartis Pharmaceuticals Corporation $9,225 2 payments

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$3,213

Medicare's payments for the services billed

Medicare patients

13

Average age 74

Services billed

67

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Heart failure 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$178,349 — —
RINVOQ
$73,508 — —
Zoryve
$56,802 — —
YCANTH
$56,761 — —
OPZELURA
$45,552 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

3,662 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Dermatology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record